SMS Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 20, 2022, titled "we are enclosing here with press release dated 20th January, 2022 regarding the Company receives non-exclusive license to manufacture and supply of molnupiravir (an oral COVID 19 medicine) through the medicine patent pool(MPP)".